AMGN vs BIIB
Figures are each company’s own, from its most recent annual filing; fiscal year ends differ. Both are classified by the SEC under Biological Products, (No Diagnostic Substances).
| Metric | AMGNAMGEN INC | BIIBBIOGEN INC. |
|---|---|---|
| Revenue | $36.75B | $9.89B |
| Gross margin | 67.2% | 75.7% |
| Operating income | $9.08B | Unavailable |
| Operating margin | 24.7% | Unavailable |
| Net income | $7.71B | $1.29B |
| Net margin | 21.0% | 13.1% |
| Free cash flow | $8.10B | $2.05B |
| Total assets | $90.59B | $29.44B |
| Total equity | $8.66B | $18.26B |
| Diluted EPS | $14.23 | $8.79 |
Every figure links to the filing it came from on each company page: AMGN and BIIB. See the methodology for how each one is chosen.